Expertise in
11
conditions

Chien-wei L. Su

No. 201, Sec. 2, Shih Pai Road, 
Taipei, TNQ, TW 
Expertise in
11
conditions
No. 201, Sec. 2, Shih Pai Road, 
Taipei, TNQ, TW 

Overview

Chien-wei Su practices practicing medicine in Taipei, Taiwan.

Su is highly rated in 11 conditions, according to our data. Their clinical expertise encompasses Liver Cancer, Hepatitis, Hepatitis B, Hepatectomy, and Cardiac Ablation.

They are actively involved in clinical research, co-authoring 199 peer reviewed articles and participating in 3 clinical trials.

Locations

No. 201, Sec. 2, Shih Pai Road, Taipei, TNQ 11217, Taiwan
Other Locations
Yuanshan Branch, Yilan, TNQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Atezolizumab Plus Bevacizumab for Patients With Advanced Hepatocellular Carcinoma (HCC) and Chronic Hepatitis B Virus (HBV) Infection
Atezolizumab Plus Bevacizumab for Patients With Advanced Hepatocellular Carcinoma (HCC) and Chronic Hepatitis B Virus (HBV) Infection
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2026
Intervention Type: Drug
Study Phase: Not Applicable
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: Lonafarnib, Ritonavir, PEG IFN-alfa-2a
Study Phase: Phase 3
A Phase 2, Randomized, Multiple-dose, Double-blind, Placebo-controlled Study of JKB-122 to Assess Liver Tests in HCV Subjects Who Have Been Nonresponsive to Prior Interferon Based Therapies Either Alone or in Combination With Ribavirin
A Phase 2, Randomized, Multiple-dose, Double-blind, Placebo-controlled Study of JKB-122 to Assess Liver Tests in HCV Subjects Who Have Been Nonresponsive to Prior Interferon Based Therapies Either Alone or in Combination With Ribavirin
Enrollment Status: Terminated
Publish Date: July 21, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

198 Total Publications

Reply to: "Comparison of patients with HBV-related HCC with and without MASLD after liver transplantation".
Reply to: "Comparison of patients with HBV-related HCC with and without MASLD after liver transplantation".
Journal: JHEP reports : innovation in hepatology
Published: June 22, 2026

Frequently Asked Questions about Chien-wei L. Su

Is Chien-wei L. Su a top-rated expert for Liver Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Chien-wei L. Su is classified as an Distinguished expert for Liver Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Chien-wei L. Su participate in research or clinical trials?

Yes. Chien-wei L. Su has published 198 articles and abstracts on conditions like Liver Cancer. You can view a list of Chien-wei L. Su's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Su's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 13 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile